Gadoteridol
- Generic Name
- Gadoteridol
- Brand Names
- Prohance
- Drug Type
- Small Molecule
- Chemical Formula
- C17H29GdN4O7
- CAS Number
- 120066-54-8
- Unique Ingredient Identifier
- 0199MV609F
- Background
Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, live...
- Indication
Gadoteridol is indicated for use with magnetic resonance imaging (MRI) in order to visualize lesions with disrupted blood-brain barrier and/or abnormal vascularity in the brain, spine, and associated tissues in adult and pediatric patients, including term neonates. It is also indicated for visualization of lesions in the head and neck in adult patients.
- Associated Conditions
- Central nervous system lesion, Lesions of the Head and Neck
- Associated Therapies
- -
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 404
- Registration Number
- NCT05915728
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
🇨🇳The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 303
- Registration Number
- NCT05915702
- Locations
- 🇺🇸
Halo Diagnostics, Indian Wells, California, United States
🇺🇸Biogenix Molecular, LLC, Miami, Florida, United States
🇺🇸Duke University School of Medicine, Durham, North Carolina, United States
Novel Imaging Markers in SPMS
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 11
- Registration Number
- NCT05357833
- Locations
- 🇺🇸
University of Utah Health Imaging and Neurosciences Center, Salt Lake City, Utah, United States
Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- OncoSynergy, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04608812
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- Conditions
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 2076
- Registration Number
- NCT04373564
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇧🇷Hospital Santa Marta, Taguatinga, Distrito Federal, Brazil
Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs
- Conditions
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 125
- Registration Number
- NCT03750188
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
- Conditions
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 24
- Registration Number
- NCT03396822
- Locations
- 🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 29
- Registration Number
- NCT02359097
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 229
- Registration Number
- NCT01613417
- Locations
- 🇺🇸
Holy Name Medical Center, Teaneck, New Jersey, United States
SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
- Conditions
- Interventions
- First Posted Date
- 2007-08-30
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 165
- Registration Number
- NCT00522951
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.